A record of what Tushar Manudhane said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on Indian generic pharma companies, expecting no impact from Trump's conditional tariffs on branded/patented drugs. The majority of Indian pharma exports to the US are generics, making it 'business as usual' for these firms. CDMO companies are also largely unaffected as they cater globally and innovator companies face hurdles in changing raw material sources.”
Nifty PharmaBullishCalled 27 Sep 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Tushar Manudhane’s full track record